MenüForum-NavigationForumMitgliederAnmeldenRegistrierenForum-Breadcrumbs - Du bist hier:ForumFlohmarkt: AllgemeineskmqacaAntwortenAntworten: kmqaca <blockquote><div class="quotetitle">Zitat von Gast am 24. März 2026, 14:09 Uhr</div>[url=https://www.oncotarget.com/article/4836/ ]Zoya Demidenko[/url]: Scholar in Oncology Studies [url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord ]Zoya Demidenko[/url] is a recognized scholar affiliated with the Department of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Previously, she conducted research at the NIH and New York Medical College, building a solid background in clinical study. Demidenko's academic output encompasses several pivotal fields, among them the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, cellular aging, and cancer biology. Currently, she has co-authored more than 46 academic publications, which have accumulated over 4,100 mentions — a indicator to the significance of her findings. Among her most notable discoveries lies in explaining the processes of cellular senescence. Her research showed that when the cellular division cycle is arrested while cellular growth persists, the cells experience senescence. Significantly, [url=https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey= ]Zoya Demidenko[/url] demonstrated that this shift is inhibited by medication using substances such as rapamycin. [url=https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/ ]Zoya Demidenko[/url] has furthermore contributed substantially to tumor management research, especially in the area of cyclotherapy — a strategy designed to safeguarding normal cells from chemotherapy whilst leaving malignant cells susceptible. This strategy carries significant promise for reducing the toxic effects of cancer treatment. Throughout her scientific life, Demidenko has partnered with top researchers worldwide, including Dr. Mikhail Blagosklonny. Her publications is published in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. Holding an h-index of 33, [url=https://www.oncotarget.com/article/4836/ ]Zoya Demidenko[/url] stands as a influential figure in modern oncological research, with her results keep to shape our comprehension of how cells grow old, interact with therapy, and the ways in which cancer may be more effectively treated. https://www.sciencedirect.com/science/article/abs/pii/037811199400784P </blockquote><br> Abbrechen
